---
title: "Pre-market hot trades in US stocks: Zhengye Biotechnology up 12.07% in pre-market; Platinum Analytics Cayman - CL down 7.80% in pre-market"
description: "Zhengye Biotechnology pre-market up 12.07%; Platinum Analytics Cayman - CL pre-market down 7.80%; PepGen pre-market up 124.44%; WORK Medical Tech pre-market up 48.44%; OFA pre-market up 44.36%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258843850.md"
published_at: "2025-09-25T09:37:06.000Z"
---

# Pre-market hot trades in US stocks: Zhengye Biotechnology up 12.07% in pre-market; Platinum Analytics Cayman - CL down 7.80% in pre-market

> Zhengye Biotechnology pre-market up 12.07%; Platinum Analytics Cayman - CL pre-market down 7.80%; PepGen pre-market up 124.44%; WORK Medical Tech pre-market up 48.44%; OFA pre-market up 44.36%

**Popular Pre-Market Trades in U.S. Stocks**

**Stocks with the Largest Pre-Market Gains in U.S. Stocks**

PepGen is up 124.44% in pre-market trading. According to recent key news:

1.  On September 25, PepGen announced a public offering of $100 million at a price of $3.20 per share, causing the stock price to soar 119.55% in after-hours trading. This move aims to fund its research and clinical trials. Source: Company announcement.
    
2.  On September 24, PepGen released positive clinical data from its FREEDOM-DM1 Phase 1 study, showing an average splice correction rate of 53.7% after a single dose of 15 mg/kg of PGN-EDODM1, driving the stock price up. Source: Company announcement.
    
3.  On September 25, Guggenheim reiterated its buy rating on PepGen and maintained a target price of $6, further boosting market confidence. Source: Analyst report. The biotechnology sector has been quite volatile recently

### Related Stocks

- [ZYBT.US - Zhengye Biotechnology](https://longbridge.com/en/quote/ZYBT.US.md)
- [PLTS.US - Platinum Analytics Cayman - CL](https://longbridge.com/en/quote/PLTS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Zydus Lifesciences 表示，美國食品藥品監督管理局（USFDA）對 Ankleshwar 二號工廠的檢查以兩項觀察結果結束 | Zydus Lifesciences 表示，USFDA 對 Ankleshwar 2 號工廠的檢查已結束，發現 2 項觀察問題 | [Link](https://longbridge.com/en/news/273514948.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.